JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
104 hedge funds and large institutions have $194M invested in Jounce Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 41 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
104
Holders Change
+2
Holders Change %
+1.96%
% of All Funds
1.85%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
17
Increased
25
Reduced
41
Closed
15
Calls
$1.06M
Puts
$1.44M
Net Calls
-$380K
Net Calls Change
-$559K
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
$12.1M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
$10.3M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
$6.48M |
| 4 |
BlackRock
New York
|
$10.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
$735K |
